1,2,3,4-四氢-8-喹啉胺 | 54012-92-9

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 1,2,3,4-四氢-8-喹啉胺
• 中文别名: 1,2,3,4-四氢喹啉-8-胺
• 英文名称: 8-amino-1,2,3,4-tetrahydroquinoline
• 英文别名: 1,2,3,4-tetrahydroquinolin-8-amine
• CAS: 54012-92-9
• 化学式: C₉H₁₂N₂
• mdl: MFCD00047566
• 分子量: 148.208
• InChiKey: LILSBXJJIIFDGR-UHFFFAOYSA-N

物化性质

• 沸点：
  145 °C
• 密度：
  1.101±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090

SDS

Name:	8-Amino-1 2 3 4-Tetrahydroquinoline (Pract) 97% (Titr.) Material Safety Data Sheet
Synonym:	1,2,3,4-Tetrahydro-8-Quinolinamine
CAS:	54012-92-9

Section 1 - Chemical Product MSDS Name:8-Amino-1 2 3 4-Tetrahydroquinoline (Pract) 97% (Titr.) Material Safety Data Sheet
Synonym:1,2,3,4-Tetrahydro-8-Quinolinamine

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
54012-92-9	8-Amino-1,2,3,4-Tetrahydroquinoline	97	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use water spray to keep fire-exposed containers cool. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Containers may explode when heated.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Cool containers with flooding quantities of water until well after fire is out. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Remove all sources of ignition. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 54012-92-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear almost colorless
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: > 110 deg C (> 230.00 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H12N2
Molecular Weight: 148.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, ignition sources, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 54012-92-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
8-Amino-1,2,3,4-Tetrahydroquinoline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 54012-92-9: No information available.
Canada
CAS# 54012-92-9 is listed on Canada's NDSL List.
CAS# 54012-92-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 54012-92-9 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,2,3,4-四氢-8-喹啉胺 在 盐酸 、 potassium carbonate 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.0h， 生成
  参考文献：
  名称：

  基于四氢喹啉的可逆LSD1抑制剂的设计，合成和生物学评估

  摘要：

  在多种肿瘤细胞中高度表达的LSD1的靶向调节是一种有前途的癌症治疗策略。几种LSD1抑制剂目前正在临床评估中，并且大多数这些抑制剂是不可逆的。在这里，我们报告基于新型四氢喹啉可逆LSD1抑制剂的设计，合成和生化评估。在MAO-A / B上对LSD1具有选择性的化合物18s和18x在分子水平上 分别表现出优异的LSD1抑制作用，IC 50 = 55 nM和540 nM。经典的Lineweaver–Burk图显示复合18s可能以非竞争性方式可逆地结合LSD1酶。分子对接用于揭示化合物的潜在结合方式并解释结构-活性关系。此外，化合物的18s和18倍显著抑制增殖（IC 50  = 1.13  μ M和1.15  μ分别用M，）和诱导细胞凋亡在MGC-803细胞与LSD1的高表达。化合物18x显示出可接受的肝微粒体稳定性。同时，18X没有出现在10〜抑制的CYP  μ中号体外。值得注意的是，口服化合

  DOI：

  10.1016/j.ejmech.2020.112243
• 作为产物：
  描述：

  8-氨基喹啉 在 二氢吡啶 、 硼酸 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 7.0h， 以87%的产率得到1,2,3,4-四氢-8-喹啉胺
  参考文献：
  名称：

  硼酸催化喹啉的化学选择性还原。

  摘要：

  硼酸促进了取代喹啉向合成多用途的1,2,3,4-四氢喹啉（1,2,3,4-THQs）的转移加氢反应，该反应在温和的反应条件下使用汉茨酯作为温和的有机氢源进行了描述。该方法是实用且有效的，其中分离的收率极好，并且在N-杂芳烃部分中可还原的官能团具有良好的耐受性。通过各种对照实验和NMR研究证明了反应参数和初步的机理途径。目前的工作也可以扩大规模以获得克量，并且通过将1,2,3,4-THQs转化为一系列具有生物学重要性的分子（包括抗心律不齐药物nicainoprol）来说明所开发方法的实用性。

  DOI：

  10.1039/c9ob02673h

文献信息

• [EN] 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS<br/>[FR] COMPOSÉS DE 4-PHÉNOXYNICOTINAMIDE OU DE 4-PHÉNOXY-PYRIMIDINE-5-CARBOXAMIDE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011089099A1

  公开（公告）日：2011-07-28

  This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula (I), wherein A1, A2, B1, B2 and R1 to R11 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

  这项发明涉及公式（I）中的新型苯基酰胺或吡啶基酰胺衍生物，其中A1、A2、B1、B2和R1至R11如描述和索赔中所定义，并且其药学上可接受的盐。这些化合物是GPBAR1激动剂，可用作治疗疾病如2型糖尿病的药物。
• Chemokine receptor binding heterocyclic compounds
  申请人：AnorMED, Inc.

  公开号：US06750348B1

  公开（公告）日：2004-06-15

  This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines. The present invention provides a compound of Formula I wherein, W is a nitrogen atom and Y is absent or, W is a carbon atom and Y═H; R1 to R7 may be the same or different and are independently selected from hydrogen or straight, branched or cyclic C1-6 alkyl; R8 is a substituted heterocyclic group or a substituted aromatic group Ar is an aromatic or heteroaromatic ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups; n and n′ are independently, 0-2; X is a group of the formula: Wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted carbon atom, an optionally substituted nitrogen atom, sulfur or oxygen atom. Ring B is an optionally substituted 5 to 7-membered ring. Ring A and Ring B in the above formula can be connected to the group W from any position via the group V, wherein V is a chemical bond, a (CH2)n″ group (where n″=0-2) or a C═O group. Z is, (1) a hydrogen atom, (2) an optionally substituted C1-6 alkyl group, (3) a C0-6 alkyl group substituted with an optionally substituted aromatic or heterocyclic group, (4) an optionally substituted C0-6 alkylamino or C3-7 cycloalkylamino group, (5) an optionally substituted carbonyl group or sulfonyl. These compounds further include any pharmaceutically acceptable acid addition salts and metal complexes thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.

  这项发明涉及一类新型的杂环化合物，它们结合趋化因子受体，抑制其天然配体的结合。这些化合物通过结合趋化因子受体，包括CXCR4和CCR5，从而抑制这些趋化因子的后续结合，产生对HIV感染的保护效果。本发明提供了一个式I的化合物 其中，W是氮原子，Y不存在，或者W是碳原子，Y═H； R1至R7可以相同也可以不同，并且独立地选择自氢或直链、支链或环状的C1-6烷基； R8是一个取代的杂环基或取代的芳香基 Ar是一个芳香或杂芳环，每个环在单个或多个非连接位置可选择地取代有电子给体或吸引体基团； n和n′独立地为0-2； X是下式的一个基团： 其中，环A是一个可选择地取代的饱和或不饱和的5或6元环，P是一个可选择地取代的碳原子、一个可选择地取代的氮原子、硫或氧原子。环B是一个可选择地取代的5到7元环。上述式中的环A和环B可以通过基团V从任何位置连接到基团W，其中V是一个化学键，一个(CH2)n″基团（其中n″=0-2）或一个C═O基团。Z是(1)一个氢原子，(2)一个可选择地取代的C1-6烷基基团，(3)一个用可选择地取代的芳香或杂环基团取代的C0-6烷基基团，(4)一个可选择地取代的C0-6烷基氨基或C3-7环烷氨基基团，(5)一个可选择地取代的羰基或磺酰基。这些化合物还包括任何药学上可接受的酸盐和金属络合物，以及它们的任何立体异构体形式和立体异构体形式的混合物。
• Actinide‐Based Porphyrinic MOF as a Dehydrogenation Catalyst
  作者：Kong‐Qiu Hu、Zhi‐Wei Huang、Zhi‐Hui Zhang、Lei Mei、Bing‐Bing Qian、Ji‐Pan Yu、Zhi‐Fang Chai、Wei‐Qun Shi

  DOI：10.1002/chem.201804284

  日期：2018.11.13

  Uranyl–organic frameworks (UOFs) have recently been the object of many research endeavors due to the unique coordination mode of uranyl ions and their attractive physicochemical properties. Here, a new (3,4)‐connected UOF (U‐IHEP‐4) assembled from uranyl and porphyrin ligand tetrakis(4‐carboxyphenyl)porphyrin (H4TCPP) is reported, which represents the first case of actinide porphyrinic MOFs. Adsorption experiments

  由于铀酰离子的独特配位模式及其吸引人的理化性质，最近，铀酰-有机骨架（UOF）成为了许多研究的对象。在这里，报道了一种新的（3,4）连接的UOF（U‐IHEP‐4），由铀酰和卟啉配体四（4-羧基苯基）卟啉（H4TCPP）组装而成，这是represents系元素卟啉MOF的第一种情况。在DMF溶液中的吸附实验表明，U‐IHEP‐4选择性吸附带正电的染料，这与其带负电的骨架和较大的孔体积比（90％）相符。值得注意的是，U-IHEP-4对N-杂环的脱氢反应具有很高的催化活性，可以合成相应的芳族杂环，并且可以用作有效的多相催化剂。
• An Unusual Chemoselective Hydrogenation of Quinoline Compounds Using Supported Gold Catalysts
  作者：Dong Ren、Lin He、Lei Yu、Ran-Sheng Ding、Yong-Mei Liu、Yong Cao、He-Yong He、Kang-Nian Fan

  DOI：10.1021/ja3066978

  日期：2012.10.24

  functional groups including halogens, ketone, and olefin remain intact during the hydrogenation of quinolines. Moreover, the protocol also shows promise for the regiospecific hydrogenation of the heterocyclic ring of a variety of other biologically important heteroaromatic nitrogen compounds, such as isoquinoline, acridine, and 7,8-benzoquinoline, in a facile manner. Apart from its importance in catalytic

  对现代可持续化学的追求刺激了创新催化工艺的发展，这些工艺能够在温和、清洁的条件下高效地进行化学转化。在此，我们报告支持在 TiO(2) 上的金纳米粒子在温和的反应条件下催化功能化喹啉与 H(2) 的化学选择性氢化。我们的结果表明喹啉在金介导的氢化反应中具有意想不到的作用，即促进剂；这与传统贵金属 Pd-、Pt- 和 Ru 基催化剂体系形成鲜明对比，其中喹啉及其衍生物通常充当毒物。由于喹啉分子对 H(2) 活化的显着促进作用超过支持的金，在非常温和的条件下（甚至在低至 25 °C 的温度下），转变可以顺利进行。具有实际意义的是各种合成有用的官能团，包括卤素、酮和烯烃，在喹啉加氢过程中保持完整。此外，该协议还显示了对各种其他生物学上重要的杂芳族氮化合物（如异喹啉、吖啶和 7,8-苯并喹啉）的杂环的区域特异性氢化的希望。除了在催化氢化中的重要性之外，我们相信反应物分子的这种有趣的自促进效应可能对
• A Proton-Responsive Annulated Mesoionic Carbene (MIC) Scaffold on Ir Complex for Proton/Hydride Shuttle: An Experimental and Computational Investigation on Reductive Amination of Aldehyde
  作者：Pragati Pandey、Prosenjit Daw、Noor U Din Reshi、Kira R. Ehmann、Markus Hölscher、Walter Leitner、Jitendra K. Bera

  DOI：10.1021/acs.organomet.0c00568

  日期：2020.11.9

  A Cp*Ir(III) complex (1) bearing a proton-responsive hydroxy unit on an annulated imidazo[1,2-a][1,8]naphthyridine based mesoionic carbene scaffold was synthesized by two different synthetic routes. The molecular structure of 1 revealed an anionic lactam form of the ligand. The acid–base equilibrium between the lactam-lactim tautomers on the ligand scaffold was examined by 1H NMR and UV–vis spectra

  通过两种不同的合成途径合成了在环状咪唑并[1,2- a ] [1,8]萘吡啶基介电卡宾骨架上带有质子响应性羟基单元的Cp * Ir（III）配合物（1）。的分子结构1揭示了配体的阴离子内酰胺形式。通过1 H NMR和UV-vis光谱检查了配体支架上内酰胺-内酯互变异构体之间的酸碱平衡。估算内酰胺形式为1的附件-OH基团的p K a，以评估催化剂的质子转移性能。1的催化功效通过使用三种不同的氢源（分子H 2，i PrOH / KO t Bu组合和HCOOH / Et 3 N（5：2）共沸混合物）评估醛的还原胺化反应。发现在三种不同的氢化方法中，HCOOH / Et 3 N（5：2）共沸混合物是最好的。在反应条件下，催化剂1在羰基上化学选择性地氢化亚胺。使用HCOOH / Et 3 N（5：2）共沸混合物将一系列醛还原为相应的仲胺。此外，催化剂1在还原多种N-杂环亚胺衍生物方面显示出高效率。提